Previous 10 | Next 10 |
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the first CellFX ® procedures in the European Union were successfully completed. The initial commercial use of ...
- Shipments of First Commercial-Use CellFX Systems to U.S. and European Dermatologists Commence - First Aesthetic Dermatology Patients Treated in the U.S. Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation&...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the fourth quarter and full year 2020 after market close on Monday, February 22, 2021. C...
Pulse Biosciences (PLSE) says it has established an at-the-market equity program that allow it to issue common shares with an aggregate gross offering price of up to $60M.Pulse says it will use sale proceeds for working capital purposes, such as the company's NPS technology out...
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation ™ (NPS ™ ) technology, today announced that it has filed a prospectus supplement with ...
- CellFX System delivers Nano-Pulse Stimulation Technology in dermatologic procedures - U.S. controlled launch to commence Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology...
Pulse Biosciences' ([[PLSE]] +10.1%) CellFX System has received CE mark approval, first commercial regulatory clearance for the system for the treatment of general dermatologic conditions, including sebaceous hyperplasia, seborrheic keratosis and cutaneous non-genital wart...
- CellFX System Delivers Nano-Pulse Stimulation Technology to Clear Hard-to-Treat Benign Skin Lesions - First CellFX System Shipment Scheduled to Commence Controlled Launch Program with Clinical Aesthetic Experts in the European Union Pulse Biosciences, Inc. (Nasdaq:...
The FDA has notified Pulse Biosciences ([[PLSE]] -2.9%) regarding its 510(k) submission for a general dermatology indication for the CellFX System that has advanced from Substantive Review to Interactive Review.The company received "Not Substantially Equivalent" letter from the FDA ...
Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced CellFX ® System regulatory progress updates. ...
News, Short Squeeze, Breakout and More Instantly...
Pulse Biosciences Inc Company Name:
PLSE Stock Symbol:
NASDAQ Market:
Pulse Biosciences Inc Website:
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the second quarter 2024 after market close on Monday, August 12, 2024. Company managemen...
2024-07-15 17:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...